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THE SOCIETAL BURDEN OF OSTEOPOROSIS
Borgström F
European Health Economics, Stockholm, Sweden
OBJECTIVE: In osteoporosis the bone mass is decreased,
thereby increasing the risk of fractures. Common osteoporotic
fractures include those at the hip, spine and forearm. Fractures
are a burden to the society; both in terms of costs, morbidity and
mortality. The main objective of this study was to investigate
some important aspects of the burden of osteoporosis in Sweden
in a health economic perspective. METHODS: The study used a
combinated incidence/prevalence bottom-up approach to esti-
mate the total annual burden of osteoporosis in Sweden. The
burden was assessed in a societal perspective including medical
care costs, non-medical care costs, informal care and indirect
costs. Moreover, the value of quality-adjusted life-years (QALYs)
foregone because of fractures was included in the total burden
estimations. RESULTS: The total annual fracture cost was esti-
mated at MSEK 6547, which is about 3.2% of the total health
care costs in Sweden. Community care was the most important
cost category accounting for 66% of the total annual cost fol-
lowed by medical care costs (31%), informal care (2%) and indi-
rect costs (1%). By combining the annual value of QALYs
foregone (MSEK 10,354) and the annual fracture costs the total
annual societal burden of osteoporosis in Sweden was estimated
at MSEK 16,901. Assuming no changes in the age-differentiated
fracture risk the burden of osteoporosis was projected to increase
to MSEK 26,301 in year 2050. CONCLUSIONS: This study
shows that the societal burden of osteoporosis in Sweden is
higher than previously perceived. The burden of osteoporosis is
substantial and has to be acknowledged as an important health
problem. Osteoporosis related fractures do not only lead to high
medical care costs but also lead to high community care costs.
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COMPARISON OF THE BURDEN OF ILLNESS OF DISPLACED
AND UNDISPLACED FEMORAL NECK FRACTURE AFTER
REDUCTION INTERNAL FIXATION
Sebestyén A1, Boncz I1,Tóth F2, Fodor B2, Betlehem J2, Nyárády J2
1National Health Insurance Fund Administration (OEP), Budapest,
Hungary, 2University of Pécs, Pécs, Hungary
OBJECTIVES: The aim of the study is to compare the burden
of displaced and undisplaced medial femoral neck fracture
treated with primary osteosynthesis in patients under 60 years
on 2 years follow up. METHODS: Data derive from the ﬁnan-
cial database of the National Health Insurance Fund Adminis-
tration and based on the S7200 code (femoral neck fracture) of
the International Classiﬁcation of Diseases (ICD) tenth revision
and the surgical codes of the Hungarian Homogenous Disease
Groups related to primary treatment of fracture in 2000. The
patients with polytrauma were excluded from the study. During
the 2 years follow up we analysed the health insurance costs,
ratio of further treatments, the ratio of multiple treatment and
mortality, while during the 3 years follow up we analysed the
50–100% impaired ability to work. The health insurance costs
include the reimbursement of acute and chronic inpatient care,
outpatient care and sick-pay costs. Exchange rate: 1 EUR =
253,23 HUF. RESULTS: Altogether 413 patients were included
into the study, 154 undisplaced and 259 displaced femoral neck
fracture. Undisplaced fracture: average cost per patient 1993
EUR for all the patients, 3682 EUR for patients with complica-
tions. The ratio of further treatment is 12.9% (secondary pros-
thesis 6.5%), ratio of multiple treatment 2.6%. Ratio of patients
with impaired ability to work was 21.4% on average. Displaced
fracture: average cost per patient 2249 EUR for all the patients,
4074 EUR for patients with complications. The ratio of further
treatment is 21.6% (secondary prosthesis 12.4%), ratio of mul-
tiple treatment 4.6%. Ratio of patients with impaired ability to
work was 25.1% on average. CONCLUSION: In case of using
osteosynthesis after displaced femoral neck fracture, the ratio of
further treatment (secondary prosthesis and multiple treat-
ments), impaired patients and the costs are signiﬁcantly higher.
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OSTEOPOROSIS RELATED HEALTH CARE UTILISATION IN
HUNGARY BY THE NATIONWIDE HEALTH INSURANCE
DATABASE
Gulácsi L1, Boncz I2, Péntek M3, Falusi Z2, Sebestyén A2,Tóth E3,
Horváth C4
1Corvinus University of Budapest, Budapest, Hungary, 2National
Health Insurance Fund Administration, Budapest, Hungary, 3Flor
Ferenc County Hospital, Kistarcsa, Hungary, 4Semmelweis University,
Budapest, Hungary
OBJECTIVES: The national health insurance database covers
97% of the population in Hungary. The aim of our study was
to assess the osteoporosis related health care utilisation and
disease management in Hungary, focussing on hip fractures and
on the activity of the qualyﬁed Osteoporosis Centre (OPC)
network. METHODS: A systematic search was performed in the
database between 1999–2003. Patients of age 50–100 with frac-
tures and/or osteoporosis were identiﬁed. Reports on visits to
OPCs, osteodensitometries were analysed by age and gender.
RESULTS: Hip fractures increased consistently (women:
8570–9180, men 2200–3480) leading to mean 556,800/40,450
acute, and 3652/1129 chronic bed days/year, respectively. A total
of 67,600 women (115,860 cases) and 5980 men (9010 cases)
visited an OPC in 1999; while 151,340 (261,550) and 13,300
(19,770) in 2003. A total 345,060 women and 36,130 men had
osteoporosis diagnosis in an OPC during the 5 years, 49% and
45% of them was 50–65 years age. A total 94–98% of the
patients had osteodensitometry in the year of the diagnosis.
47.1%, 37.9% and 38.1% of women with hip, forearm or shoul-
der fracture did not have osteoprosis diagnosis during the 5 years
(men: 89.1%, 88.6%, 88.8%). Osteodensitometry was per-
formed in 5%, 13% and 11.6% of women with hip, forearm or
shoulder fracture in 1999, slightly higher rates occurred in 2002
(6.9%, 18.8% and 16%); lower proportions were observed in
males (2.2–2.9%) and 3–5% of the patients had osteoporosis
diagnosis. CONCLUSIONS: Hip fracture has a signiﬁcant
burden on the health care system in Hungary. Osteoporosis
related health care utilisation increased consistently in the time
period observed. However, the rate of patients screened for
osteoporosis before fracture was rather low and patient ways for
osteporosis management after fracture were not guaranteed. Our
study provide helpful data for further target population identiﬁ-
cation and health care improvement projects.
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EVOLUTION OF THE CONSUMPTION OF BISPHOSPHONATES
AND RALOXIFENE FINANCED BY THE SPANISH NATIONAL
HEALTH SYSTEM FOR OSTEOPOROSIS IN
POSTMENOPAUSAL WOMEN
Gaspar MD
University of Barcelona, Barcelona, Spain
OBJECTIVES: Osteoporosis affects a 35% of the Spanish
women over 50. This percentage rises to 52% in those who are
over 70. Currently, bisphosphonates (alendronate, etidronate
and risedronate) and raloxifene are approved by the Spanish
Agency of Medicines and Health care Products for preventing
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and treating osteoporosis in postmenopausal women (PW). In
addition, these are the ﬁrst option of treatment (the Spanish Bone
and Mineral Society -SEIOMM) in the Clinical Practice Guide-
lines (GPC) (2003). Here, we analyse the evolution of con-
sumption of bisphosphonates and raloxifene in Spanish PW
(over 50), during the period 1999 to 2004. METHODS: A ret-
rospective analysis of the consumption was made, selecting the
four drugs for osteoporosis in PW treatment. Paget’s disease data
were not included. Drug consumption data were provided by the
Ministry of Health and Consume Database. The ﬁgures are pre-
sented as number of dispensed units (standard package), as
numbers of DDDs / 1000 PW / day, according to the ATC/DDD
system, Index 2006, and as Euros (Price to Customer tax-free) /
Dispensed DDDs / 1000 PW / day. Demographics were consulted
in the Spanish INE Database. RESULTS: The number of dis-
pensed units of Alendronate, Risedronate and Raloxifene
between 2003 and 2004 were 43.41%, 126.62%, and 19.75%,
respectively. Only Etidronate decreased, but only a 9.64%. From
among the results to emphasize the ﬁgures of DDDs / 1000 
PW / day between 2003 and 2004 that show also this increases
(15.87%, 60.18%, and 1.45% for Alendronate, Risedronate and
Raloxifene, respectively). Alendronate presented the higher cost
in 2004 (€12,297,15/DDDs/1000 PW/day. CONCLUSIONS:
The indicators used in this study have permitted establish that
dispensing data of osteoporosis in PW treatment ﬁnanced by
Spanish NHS had a signiﬁcant increase in 2004. These data coin-
cide with the implement of the Spanish GPC.
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THE DIFFUSION OF NEW DRUG IN TAIWAN MEDICAL CARE
UNDER NATIONAL HEALTH INSURANCE: THE CASE OF
COX2
Tsai YW1, Huang WF2,Wen YW3, Chen PF3
1National Health Research Institutes, Zhunan Town,Taiwan, 2National
Yang-Ming University,Taipei,Taiwan, 3National Health Research
Institutes, Miaoli County,Taiwan
OBJECTIVES: Adoption of new drug in medical care, a highly-
regulated industry, is and essential in terms of access to new
treatment option and raise on health care expenditure. This
study, using Cox2 as example, is to examine the diffusion of new
drug among hospitals of different characteristics. METHOD:
The data were drawn from systematic random sample of NHI
claim data in 1997 to 2001. We applied the Bass diffusion model
to analyze the monthly number of each hospital’s outpatient
clinic visits with COX2. Bass diffusion model based on the initial
time of purchase of product to explains the behavior of the dif-
fusion of the product in the market: length to reach maximum
monthly volume, maximum monthly volume, growth rate.
RESULTS: The estimates of Bass diffusion model shows that the
monthly numbers of outpatient clinic visits with COX2 pre-
scription reached the stable maximum in the 92th month, 41
months after the introduction of COX2 on April of 2001. The
length of growth period for reaching maximum volume varied
with different accreditation level of hospital: academic medical
center 38 months, metropolitan hospitals 43 months, local com-
munity hospitals 40 months, and physician clinics 51 months.
The average of maximum volume for academic center was 76.17
outpatient visits, metropolitan hospitals 87.25 visits, local com-
munity hospitals 62.65 visits, and physician clinics 34.38 visits.
Physician clinics has the fast growth rate (q = 0.1278), in con-
trast to the slowest of local community hospitals (q = 0.1159),
CONCLUSION: Hospitals of different level vary in terms of
adopting new drugs. Academic medical centers play the role of
innovators.
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THE ESTIMATION OF COST–EFFECTIVENESS THRESHOLDS
PRIOR TO THE START OF LARGE CLINICAL STUDIES
Van Staa TP1, Cooper C2, Leufkens HG3
1General Practice Research Database, London, UK, 2University of
Southampton, Southampton, UK, 3Utrecht University, Utrecht,The
Netherlands
OBJECTIVES: Cost-effectiveness analyses are currently con-
ducted after the conduct of expensive clinical trials. An approach
was developed to estimate cost-effectiveness thresholds prior to
clinical studies, comparable to statistical power calculations.
METHODS: A new osteoporosis treatment was taken as
example, with different scenarios of treatment efﬁcacy and costs.
Data on fracture and mortality risks were obtained from the
General Practice Research Database. These risks were estimated
individually by age, sex, fracture history, body mass index,
smoking and other risk factors. EQ5D utilities were obtained
from a UK national report (NICE) and outcomes were simulated
over a 10-year period (5-year treatment), using a cost-
acceptability ratio of £30k per QALY gained. RESULTS: The 
5-year risk of osteoporotic fracture required to reach the cost-
effectiveness threshold was 17.1% (95% conﬁdence interval
15.0–19.3%) with a fracture efﬁcacy of 0.50 at an annual cost
of £1000. This was 6.1% (5.2–7.0%) with a cost of £250 and
3.7% (3.1–4.5% with a cost of £100. With a fracture efﬁcacy of
only 0.80, these threshold risks were 34.7% (23.2–38.7%),
10.7% (8.3–14.5%) and 5.4% (3.8–7.8%), respectively. At a T-
score of −2.5 and fracture efﬁcacy of 0.80 and cost of £250,
patients without a fracture history would require additional risk
factors (with a relative rate of 2.5) in order to reach the thresh-
old, while this would be reached by the average woman at 
age 85. However, with a cost of £1000, this threshold would
only be reached at age 55 with additional risk factors with 
RR of 9.5 and at age 85 with RR of 3.0. CONCLUSION: Cost-
effectiveness thresholds can be estimated prior to expensive clin-
ical trials using high-quality health care databases. Similar to
statistical power calculations, they can then be used to guide
patient selection into the clinical trials, by providing information
on the required minimum levels of risks.
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QUALITY OF LIFE ACCORDING TO EQ-5D AFTER
OSTEOPOROTIC HIP FRACTURE IN POLAND
Golicki D1, Sliwka A1, Fijewski G2, Latek M3
1Medical University of Warsaw, Warsaw, Poland, 2Medical University of
Warsaw, Department of Orthopaedics and Traumatology of
Locomotor System, Warsaw, Poland, 3Warsaw School of Economics,
Warszawa, Poland
OBJECTIVES: To assess changes in health related quality of life
(HRQoL) in patients with osteoporotic hip fracture in Poland
using EQ-5D. METHODS: 104 patients (82 women and 22 men;
mean age 80.1 years), hospitalized between March 2004 and
March 2005, with osteoporotic hip fracture were included in a
prospective clinical trial. The inclusion criteria was: age at least
60 years, low energy femoral neck fracture or pertrochanteric
fracture of the femur and absence of severe cognitive dysfunc-
tion as measured by Hodkinson’s Abbreviated Mental Test Score.
Quality of life was measured with descriptive part of Polish
version of generic questionnaire EQ-5D. The reference European
value set (BIOMED) was used. During the ﬁrst 72 hours after
hospitalisation, patients were asked to rate their HRQoL during
the month before fracture. The follow-up took place at 10 days
and 14 months after the injury. RESULTS: Eighty three patients
were avaiable at the ﬁnal follow-up (11 were ceased and 10 lost
to follow-up). Mean EQ-5D Index increased signiﬁcantly 14
